Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) have been assigned an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $42.67.

Separately, Mizuho boosted their price target on Cerevel Therapeutics from $25.00 to $45.00 and gave the stock a “neutral” rating in a report on Friday, February 16th.

Cerevel Therapeutics Stock Down 0.5 %

CERE opened at $42.06 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 10.92 and a current ratio of 10.92. The firm’s fifty day moving average is $42.04 and its 200 day moving average is $38.14. The stock has a market cap of $7.64 billion, a price-to-earnings ratio of -16.82 and a beta of 1.46. Cerevel Therapeutics has a fifty-two week low of $19.59 and a fifty-two week high of $43.59.

Insider Buying and Selling at Cerevel Therapeutics

In other Cerevel Therapeutics news, Director N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock in a transaction on Monday, March 4th. The shares were sold at an average price of $41.01, for a total value of $2,050,500.00. Following the completion of the transaction, the director now directly owns 15,638 shares of the company’s stock, valued at approximately $641,314.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.10% of the stock is owned by company insiders.

Institutional Trading of Cerevel Therapeutics

Institutional investors have recently bought and sold shares of the stock. Entropy Technologies LP purchased a new stake in shares of Cerevel Therapeutics in the first quarter valued at $682,000. Headlands Technologies LLC purchased a new stake in Cerevel Therapeutics in the 1st quarter worth about $26,000. Sei Investments Co. bought a new stake in Cerevel Therapeutics in the first quarter worth about $660,000. Swiss National Bank lifted its stake in Cerevel Therapeutics by 2.5% in the first quarter. Swiss National Bank now owns 143,200 shares of the biotechnology company’s stock worth $6,053,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Deuterium Capital Management LLC purchased a new position in shares of Cerevel Therapeutics during the first quarter valued at approximately $531,000. 87.73% of the stock is currently owned by institutional investors.

Cerevel Therapeutics Company Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.